Compare 10X Genomics Inc (TXG) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? 10X Genomics Inc trades at $57.31 (market cap $7.61B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.42. Which is the better fit depends on your goals.
| TXG | VWO | |
|---|---|---|
Market Cap | $7.61B | — |
Sector | Health | — |
52-Week High | $58.57 | $61.24 |
52-Week Low | $11.34 | $51.20 |
Enterprise Value | $7.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
VWO trades at $60.42, up 0.15% today, with a bullish technical signal driven by moving averages. The ETF shows strong institutional accumulation, with Barry Investment Advisors increasing holdings by 6.1% (SEC filing, August 10, 2026). RSI levels indicate mild overbought conditions, while support sits near $60.
Outlook remains positive due to record capital inflows into emerging markets and low 0.06% expense ratio. Risks include concentrated exposure to developing economies and China's economic volatility. The dividend yield of 2.4% offers income appeal amid global diversification trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
